Short-term risk of falls among initiators of controlled-release tapentadol versus oxycodone in New South Wales between 2014 and 2020: A population-based retrospective cohort study
PLOS Medicine · 11.08.2026 · 23 (8) · e1004950
DOI: 10.1371/journal.pmed.1004950 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift PLOS Medicine, online erschienen am 11.08.2026. Verfasst von Ximena Camacho und 9 weiteren Autor:innen. Beteiligte Einrichtung: Centre of Research Excellence in Medicines Intelligence, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Oxycodone, Tapentadol, Analgesics, Opioid, Accidental Falls. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council, Fonds de Recherche du Québec - Santé, McGill University.
Themen: Sturzprophylaxe
Abstract (Originalsprache)
Background
Clinical trials comparing sustained-release (SR) tapentadol with controlled-release (CR) oxycodone have suggested that tapentadol (SR) may be associated with fewer nervous system side effects. However, it remains important to evaluate the relative safety of these agents in real-world clinical settings. Given the potential severity and economic burden of falls, together with their established association with opioid use, we compared the short-term risk of falls following initiation of tapentadol (SR) versus oxycodone (CR) in routine clinical practice. Methods and findings We conducted an active comparator, new user retrospective cohort study using linked routinely collected health data on residents of New South Wales, Australia (2014–2020). We included people aged ≥18 years initiating publicly subsidised tapentadol (SR) or oxycodone (CR). Our outcome was a composite measure of fall-related emergency department presentations, hospitalisations or deaths. We used propensity score matching to adjust for baseline confounding and approximated relative risks (RR) of falls at 7, 14, and 28 days after initiation using conditional logistic regression models. We calculated absolute risk differences and estimated the number of people that would need to be treated with oxycodone (CR) versus tapentadol (SR) for one additional fall to occur (NNTH). We conducted subgroup analyses restricted to people aged ≥65 and ≥80 years and by recent opioid exposure (within 90 days prior to initiation). We identified 103,924 tapentadol (SR) and 419,732 oxycodone (CR) initiators; after matching each cohort comprised 103,758 initiators. Most people (74%) were aged between 45 and 84 years, and slightly more than half were female. Within 28 days of initiation, 652 (0.6%) oxycodone (CR) initiators and 457 (0.4%) tapentadol initiators experienced a fall. Across all time points, tapentadol (SR) initiation was associated with a lower risk of falls compared with oxycodone (CR) (7 days: RR 0.57 [95% CI: 0.48, 0.69]; 14 days: RR 0.62 [95% CI: 0.54, 0.71]; 28 days: RR 0.70 [95% CI: 0.62, 0.79]). Absolute differences were small at all time points (approximately 1–2 fewer falls per 1,000 patients treated), corresponding to NNTH for one additional fall ranging from 739 to 529. These patterns persisted regardless of recent opioid exposure. Relative risks were similar in the older age groups while absolute differences were slightly larger (≥65 years: 2–3 fewer falls/1,000; ≥80 years: 4–8 fewer falls/1,000). The greatest absolute differences were among opioid-naïve people aged ≥80 years (6–10 fewer falls/1,000, corresponding to NNTH ranging from 173 to 97). Fall risks were attenuated among people aged ≥80 years with recent opioid exposure. The main limitations of this study were that we did not have data on immediate-release tapentadol, or on falls that did not result in emergency department presentations or hospitalisations but may have otherwise impacted independence and mobility.
Conclusions
Tapentadol (SR) was associated with a lower risk of falls than oxycodone (CR) up to four weeks after initiation, although absolute differences were small. The reduction in risk may be an important consideration in older patients where the consequences of falls are most severe.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Centre of Research Excellence in Medicines Intelligence, Sydney, New South Wales, Australia.
- School of Population Health, Faculty of Medicine and Health, UNSW Sydney, Sydney, New South Wales, Australia.
- The Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.
- Clinical Pharmacology and Toxicology, St Vincent's Hospital, Sydney, New South Wales, Australia.
- National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, New South Wales, Australia.
- Centre for Clinical Epidemiology, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Québec, Canada.
ORCID-Profile: Ximena Camacho, Andrea L Schaffer, Jonathan Brett, Kristian B Filion, Nicole Pratt, David Henry, Sallie-Anne Pearson
Förderung
- National Health and Medical Research Council
- Fonds de Recherche du Québec - Santé
- McGill University
Zitieren
APA
Camacho, X., Schaffer, A. L., Brett, J., Hopkins, R., Gisev, N., Marsh, S., Filion, K. B., Pratt, N., Henry, D., & Pearson, S. A. (2026). Short-term risk of falls among initiators of controlled-release tapentadol versus oxycodone in New South Wales between 2014 and 2020: A population-based retrospective cohort study. PLOS Medicine, 23(8), e1004950. https://doi.org/10.1371/journal.pmed.1004950
Vancouver
Camacho X, Schaffer AL, Brett J, Hopkins R, Gisev N, Marsh S, et al. Short-term risk of falls among initiators of controlled-release tapentadol versus oxycodone in New South Wales between 2014 and 2020: A population-based retrospective cohort study. PLOS Medicine. 2026;23(8):e1004950. doi:10.1371/journal.pmed.1004950
BibTeX
@article{Camacho2026,
author = {Camacho, Ximena and Schaffer, Andrea L and Brett, Jonathan and Hopkins, Ria and Gisev, Natasa and Marsh, Steven and Filion, Kristian B and Pratt, Nicole and Henry, David and Pearson, Sallie-Anne},
title = {Short-term risk of falls among initiators of controlled-release tapentadol versus oxycodone in New South Wales between 2014 and 2020: A population-based retrospective cohort study},
journal = {PLOS Medicine},
year = {2026},
volume = {23},
number = {8},
pages = {e1004950},
doi = {10.1371/journal.pmed.1004950}
}
EUVIMED